VK2735: what it is and where the research stands

It is a peptide with a side chain that extends its duration of action, so that one injection a week is enough. In laboratory measurements it binds both receptors: IC50 188 nM for GLP-1 and 325 nM for GIP. These values are the company's unpublished data, as quoted in the Phase 2 paper.

An important gap: the company has not published the amino-acid sequence, length or molecular weight. Any structure circulating on other websites does not come from an official source.

• VENTURE (NCT06068946): Form: Injection · Phase: 2 · Participants: 176 · Status: Completed, published
• VANQUISH-1 (NCT07104500): Form: Injection, without diabetes, 78 weeks · Phase: 3 · Participants: about 4,500 · Status: Fully enrolled
• VANQUISH-2 (NCT07104383): Form: Injection, with type 2 diabetes, 78 weeks · Phase: 3 · Participants: about 1,100 · Status: Fully enrolled
• VENTURE-Oral (NCT06828055): Form: Tablet · Phase: 2 · Participants: 280 · Status: Completed, company announcement
• Two tablet trials (NCT07868835, NCT07868939): Form: Tablet · Phase: 3 · Participants: 560 each · Status: Not yet started

For both VANQUISH trials the registry lists 1 July 2027 as the estimated primary completion. The company has not announced a results date.

Phase 2, injection, 13 weeks — peer-reviewed (Obesity 2026, PMID 41508550). Among 176 adults with a BMI of 30 or more, or 27 or more with a related condition, without diabetes, the mean change in body weight from baseline was:

• Placebo: Weight change: −1.7% · Share with ≥10% loss: 3.0%
• 2.5 mg: Weight change: −9.1% · Share with ≥10% loss: 40.1%
• 5 mg: Weight change: −10.9% · Share with ≥10% loss: 65.1%
• 10 mg: Weight change: −12.9% · Share with ≥10% loss: 70.4%
• 15 mg: Weight change: −14.7% · Share with ≥10% loss: 89.1%

The study lasted only 13 weeks and all participants received lifestyle counselling. Of 74 participants with prediabetes, 58 (78%) had normal blood sugar at the end. This was a secondary result and does not show whether the effect is maintained.

Early study, 28 days — company announcement (28 Mar 2023). In healthy adults with a BMI of 30 or more, mean weight reduction reached up to 7.8% from baseline.

Maintenance study — company announcement, not peer-reviewed (22 Sep 2026). After 21 weeks of weekly dosing, the company reports that less frequent dosing (every other week or monthly), over 12 weeks, was associated with keeping most of the weight that had been lost. Detailed data have not been published.

Tablet, 13 weeks — company announcement (19 Aug 2025). At 120 mg daily the mean weight reduction was 12.2%, versus 1.3% on placebo, among 280 participants. The tablet figures must not be mixed up with the injection figures: they come from different studies and populations and are not compared with each other.

Clinical-trial facts, not usage instructions. VK2735 is an investigational compound without approval.

Injection, once weekly, subcutaneous.

• VENTURE: final doses of 2.5, 5, 10 and 15 mg. According to the company's poster, the dose rose by 2.5 mg every 3 weeks. The 15 mg group started at 5 mg rather than 2.5 mg.
• VANQUISH: three final doses, 7.5, 12.5 and 17.5 mg, against placebo. The company's poster shows a stepwise increase from 1.25 mg. The time per step is not reliably stated and we do not report it.
• Maintenance study: the highest dose reported in humans is 22.5 mg weekly (company announcement).

Tablet, once daily (separate): 15 to 120 mg daily in Phase 2.

The company reports a half-life of about 170 to 250 hours after a single dose, and 171 hours at the 5 mg dose in VENTURE. These figures come from a company announcement and poster, not from a peer-reviewed paper.

In the published VENTURE study, the most common drug-related adverse events were:

• nausea: 36.6% (64 of 175)
• constipation: 21.1%
• vomiting: 12.6%

Nausea ranged from 26% at the lowest dose to 63% at 15 mg, versus 20% on placebo. Sixteen of 175 (9.1%) stopped because of an adverse event. Serious events were reported in 8 of 175 (4.6%). Heart rate rose by 3.3 to 9.3 beats per minute in the drug groups, versus 1.4 on placebo. Anti-drug antibodies were found in 9 to 23% at 13 weeks. No pancreatitis was reported.

Trials excluded people with a history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2, a history of pancreatitis, and (in VENTURE and VANQUISH-1) diabetes. These are trial exclusion criteria, not official contraindications, because there is no approved medicine.

• Its structure: sequence, length and molecular weight are unpublished.
• Phase 3 results. None exist yet.
• Detailed maintenance and tablet data. They exist only as company announcements.

This content is educational and research-oriented. VK2735 is an investigational compound, is not approved as a medicine, and is not intended for human use. This is not medical advice.